Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYDROSAPL: Hydroxychloroquine in Primary Obstetric Antiphospholipid Syndrome
NCT04275778Phase 2Withdrawn
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hydroxychloroquine in antiphospholipid syndrome (APS), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Jul 2021; status: withdrawn.
02
Drugs
hydroxychloroquine
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on NCT04275778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04275778.